Related Experiment Video

Updated: Aug 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Dilzem-retard efficiency in patients with ischemic heart disease and heart failure]

A N Gadzhiev

    Klinicheskaia Meditsina
    |July 26, 2002
    PubMed

    Insights

    This study shows that Dilcem-retard, a prolonged diltiazem form, effectively treats stable effort angina and chronic cardiac failure. It improved patient condition, exercise tolerance, and cardiac function over six months.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Stable effort angina and chronic cardiac failure (NYHA class II) significantly impact patient quality of life.
    • Prolonged-release calcium channel blockers are explored for managing these conditions.

    Purpose of the Study:

    • To evaluate the effectiveness of Dilcem-retard (prolonged-release diltiazem) in patients with stable effort angina and chronic cardiac failure.
    • To assess the impact of Dilcem-retard on clinical status, exercise capacity, and cardiac function.

    Main Methods:

    • A 6-month clinical trial involving 20 patients with stable effort angina and NYHA class II chronic cardiac failure.
    • Administration of Dilcem-retard at 180 mg/day.
    • Assessment of clinical condition, exercise tolerance, left ventricular parameters, heart rhythm variability, late potentials, and Holter monitoring before and after treatment.

    Main Results:

    • Dilcem-retard demonstrated significant improvement in patients' clinical condition and exercise tolerance.
    • Normalization of left ventricular diastolic function was observed.
    • No adverse effects on cardiac output were noted.
    • A reduction in sympathicotonia and late potentials was documented.

    Conclusions:

    • Prolonged-release diltiazem (Dilcem-retard) is an effective treatment for patients with stable effort angina and chronic cardiac failure.
    • Dilcem-retard improves cardiac function and exercise capacity without negatively impacting cardiac output.
    • The drug also shows potential in reducing indicators of autonomic dysfunction and arrhythmogenic substrates.

    More Related Videos

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

    Published on: July 21, 2023

    Related Concept Videos

    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...